ClinicalTrials.gg
CompletedNCT00443898Updated May 3, 2012Results posted

Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail

A Phase 3 interventional study of terbinafine and Placebo in Onychomycosis, sponsored by Novartis Pharmaceuticals. Completed at 22 sites in 3 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-05-03.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
518
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing terbinafine in Onychomycosis — 1 open to participants now, 2 under way, 1 of them phase 3. Terbinafine · Onychomycosis.

Enrollment
4th of 19
518 · median 100
Started
2006
with 1 other
Phase 3
10 of 20
none open now
Registered
2nd of 20
by date
Lead sponsor
2 of 20
Novartis Pharmaceuticals

Among the 20 studies testing terbinafine in Onychomycosis, this one is the 4th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2006, is one of 10 in phase 3, and was the 2nd registered.

Onychomycosis

158 studies on the registry are indexed under Onychomycosis; 16 are open to participants now.

Browse Onychomycosis studies →

Open to participants now

1 of the 20 studies testing terbinafine in Onychomycosis is open now. Recruiting first, the newest first:

About terbinafine

Terbinafine: first FDA approval 1992 (LAMISIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 9 Onychomycosis studies recruiting now, 3 set no upper age limit and 5 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing terbinafine in Onychomycosis, or all of them as a file.
02

Study summary

This study is designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine solution applied daily in patients with toenail fungus. This trial will study patients with mild to moderate toenail fungus disease of the big toenail and their responses to two treatment durations, 24 or 48 weeks.

03

Conditions studied

  • Onychomycosis

Browse trials for

Keywords

  • Toenail fungus
  • Onychomycosis
  • Nail fungus
  • Toenail fungal infection
  • Tinea unguium
  • Dermatophytes
  • Foot dermatoses
04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and females 12 - 75 years of age
  • Fungal toenail infection of one or both of the large (great) toenails
  • The nail infection must be due to a dermatophyte, (mixed infections [dermatophyte and non-dermatophyte] are not allowed)

Exclusion criteria

Exclusion Criteria:

  • Target foot must not have severe plantar (moccasin) tinea pedis that would require systemic therapy. Mild to moderate tinea pedis (athlete's foot) infection should be treated with terbinifine prior to baseline or at any time during the trial. Other topical treatments for athlete's foot may be recommended at the discretion of the investigator.
  • Subjects must not have abnormalities of the nail that could prevent a normal appearing nail if clearing of infection is achieved
  • No administration of systemic antifungal medications within 6 months prior to screening visit
  • No application of prescription topical antifungal medications for toenail fungus within 3 months or other commercially available topical medications for toenail fungus applied directly to the toenails within 1 month prior to screening visit
  • No professional pedicures or application of any nail polish product or nail cosmetic to the toenails after the screening visit
  • Known pregnancy or lactation at time of enrollment

Other protocol-defined inclusion/exclusion criteria may apply

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
518 participants (actual)

Study arms

  • Experimental
    1

    Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 48 weeks

    Drug: terbinafine

  • Placebo comparator
    2

    vehicle (placebo) applied once daily for 48 weeks

    Drug: Placebo

  • Experimental
    3

    Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 24 weeks

    Drug: terbinafine

  • Placebo comparator
    4

    vehicle (placebo) applied once daily for 24 weeks

    Drug: Placebo

Interventions

  • Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 48 weeks

    Also known as: Lamisil

  • DrugPlacebo

    vehicle (placebo) applied once daily for 48 weeks

  • Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 24 weeks

    Also known as: Lamisil

  • DrugPlacebo

    vehicle (placebo) applied once daily for 24 weeks

06

What researchers measure

Primary outcomes

  1. Efficacy Assessed by Complete Cure Rate at the End of Study (Week 52) After Treating for 24 or 48 Weeks.

    Complete cure is defined as negative KOH microscopy and negative culture for dermatophytes. and no residual involvement of the target toenail. The complete cure was a composite binary variable defined as "Yes" if: * Mycological cure (negative KOH and negative culture for dermatophytes) and * No residual involvement of the target toenail "No" if otherwise

    Time frame: 52 weeks

Secondary outcomes

  1. Efficacy Assessed by Mycological Cure (Negative Culture and Negative KOH Microscopy) at the End of Study After Treating Patients for 24 or 48 Weeks.

    Mycological cure is defined as negative KOH microscopy and negative culture for dermatophytes. Mycological cure was a composite binary variable defined as "Yes"if : * Negative microscopy and * Negative culture for dermatophytes "No" if otherwise.

    Time frame: 52 weeks

  2. Efficacy Assessed by Clinical Efficacy at the End of Study After Treating Patients for 24 or 48 Weeks.

    Clinical effectiveness is defined as negative KOH microscopy and negative culture for dermatophytes and \<= 10% residual involvement of the target toenail. Clinical effectiveness was a composite binary variable defined as "Yes" if * Mycological cure (negative KOH and negative culture for dermatophytes) and * = 10% residual involvement of the target toenail "No" if otherwise

    Time frame: 52 weeks

  3. Number of Participants Assessed With Adverse Events and Serious Adverse Events

    An adverse event (AE) is any adverse change in health or side effect that occurs while the participant is receiving the treatment or within a previously specified period of time after the treatment has been completed. A Serious Adverse Event (SAE) is any untoward medical occurrence that results in death, is life-threatening requires, inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage.

    Time frame: 52 weeks

07

Results

Posted Apr 20, 2011

Participant flow

Participant flow — Overall Study
MilestoneTerbinafine 24 wVehicle 24 wTerbinafine 48 wVehicle 48 w
Started126128136128
Completed102103107110
Not completed24252918
Withdrew: Adverse event0011
Withdrew: Lack of efficacy2331
Withdrew: Protocol violation1110
Withdrew: Withdrawal by subject1110106
Withdrew: Lost to follow-up10101410
Withdrew: Death0100

Outcome measures

PrimaryEfficacy Assessed by Complete Cure Rate at the End of Study (Week 52) After Treating for 24 or 48 Weeks.

Complete cure is defined as negative KOH microscopy and negative culture for dermatophytes. and no residual involvement of the target toenail. The complete cure was a composite binary variable defined as "Yes" if: * Mycological cure (negative KOH and negative culture for dermatophytes) and * No residual involvement of the target toenail "No" if otherwise

Time frame:
52 weeks
Reported as:
Number · Percentage of Participants
Efficacy Assessed by Complete Cure Rate at the End of Study (Week 52) After Treating for 24 or 48 Weeks.
Percentage of ParticipantsTerbinafine 24 wVehicle 24 wTerbinafine 48 wVehicle 48 w
Efficacy Assessed by Complete Cure Rate at the End of Study (Week 52) After Treating for 24 or 48 Weeks.0.79 (-2.16 to 2.19)0.78 (-2.16 to -2.16)1.47 (-0.55 to 3.49)0.00 (-0.55 to 3.49)
SecondaryEfficacy Assessed by Mycological Cure (Negative Culture and Negative KOH Microscopy) at the End of Study After Treating Patients for 24 or 48 Weeks.

Mycological cure is defined as negative KOH microscopy and negative culture for dermatophytes. Mycological cure was a composite binary variable defined as "Yes"if : * Negative microscopy and * Negative culture for dermatophytes "No" if otherwise.

Time frame:
52 weeks
Reported as:
Number · Percentage of Participants
Efficacy Assessed by Mycological Cure (Negative Culture and Negative KOH Microscopy) at the End of Study After Treating Patients for 24 or 48 Weeks.
Percentage of ParticipantsTerbinafine 24 wVehicle 24 wTerbinafine 48 wVehicle 48 w
Efficacy Assessed by Mycological Cure (Negative Culture and Negative KOH Microscopy) at the End of Study After Treating Patients for 24 or 48 Weeks.10.32 (-2.70 to 10.83)6.25 (-2.70 to 10.83)15.44 (5.54 to 19.10)3.13 (5.54 to 19.10)
SecondaryEfficacy Assessed by Clinical Efficacy at the End of Study After Treating Patients for 24 or 48 Weeks.

Clinical effectiveness is defined as negative KOH microscopy and negative culture for dermatophytes and \<= 10% residual involvement of the target toenail. Clinical effectiveness was a composite binary variable defined as "Yes" if * Mycological cure (negative KOH and negative culture for dermatophytes) and * = 10% residual involvement of the target toenail "No" if otherwise

Time frame:
52 weeks
Reported as:
Number · Percentage of Participants
Efficacy Assessed by Clinical Efficacy at the End of Study After Treating Patients for 24 or 48 Weeks.
Percentage of ParticipantsTerbinafine 24 wVehicle 24 wTerbinafine 48 wVehicle 48 w
Efficacy Assessed by Clinical Efficacy at the End of Study After Treating Patients for 24 or 48 Weeks.1.592.343.681.56
SecondaryNumber of Participants Assessed With Adverse Events and Serious Adverse Events

An adverse event (AE) is any adverse change in health or side effect that occurs while the participant is receiving the treatment or within a previously specified period of time after the treatment has been completed. A Serious Adverse Event (SAE) is any untoward medical occurrence that results in death, is life-threatening requires, inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage.

Time frame:
52 weeks
Reported as:
Number · Participants
Number of Participants Assessed With Adverse Events and Serious Adverse Events
ParticipantsTerbinafine 24 wVehicle 24 wTerbinafine 48 wVehicle 48 w
Number of Participants Assessed With Adverse Events and Serious Adverse Events126124135128

Adverse events

Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Terbinafine 24 w—2/126 (1.6%)35/126 (27.8%)
Vehicle 24 w—7/124 (5.6%)38/124 (30.6%)
Terbinafine 48 w—7/135 (5.2%)47/135 (34.8%)
Vehicle 48 w—4/128 (3.1%)56/128 (43.8%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventTerbinafine 24 wVehicle 24 wTerbinafine 48 wVehicle 48 w
AppendicitisInfections and infestations0/1260/1242/1350/128
Accidental deathGeneral disorders0/1261/1240/1350/128
PneumoniaInfections and infestations0/1261/1240/1350/128
Tendon ruptureInjury, poisoning and procedural complications0/1261/1240/1350/128
Endometrial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1261/1240/1350/128
Metastatic malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1261/1240/1350/128
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1261/1241/1350/128
SyncopeNervous system disorders0/1261/1240/1350/128
Syncope vasovagalNervous system disorders0/1261/1240/1350/128
ConvulsionNervous system disorders1/1260/1240/1350/128
Most frequent other events
Most frequent other events
EventTerbinafine 24 wVehicle 24 wTerbinafine 48 wVehicle 48 w
HeadacheNervous system disorders23/12624/12423/13529/128
NasopharyngitisInfections and infestations7/1269/12418/13518/128
Back painMusculoskeletal and connective tissue disorders7/1267/1249/13510/128
Influenza like illnessGeneral disorders2/1261/1240/1358/128
Upper respiratory tract infectionInfections and infestations4/1266/1248/1358/128

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Terbinafine 24 wVehicle 24 wTerbinafine 48 wVehicle 48 wTotal
<=18 years00000
Between 18 and 65 years107101116100424
>=65 years1927202894
Sex: Female, Male
Sex: Female, Male(Participants)Terbinafine 24 wVehicle 24 wTerbinafine 48 wVehicle 48 wTotal
Female25292627107
Male10199110101411
08

Study locations

22 sites
  • Dr. Boni Elewski
    Birmingham, Alabama 35233, United States
  • Dr. Stacy Smith
    San Diego, California 92123, United States
  • Dr. James Swinehart
    Denver, Colorado 80210, United States
  • Dr. David G. Armstrong
    North Chicago, Illinois 60064, United States
  • Dr. Kevin Terry
    Lutherville, Maryland 21093, United States
  • Dr. Anthony Puopolo
    Milford, Massachusetts 01757, United States
  • Dr. John Fenyk
    Chaska, Minnesota 55318, United States
  • Dr. Joel Schlessinger
    Omaha, Nebraska 68144, United States
  • Dr. AnneMarie Uliasz
    New York, New York 10029, United States
  • Dr. Willard Niemi
    Raleigh, North Carolina 27615, United States
  • Dr. Diane Baker
    Lake Oswego, Oregon 97035, United States
  • Dr. John Barnes
    Portland, Oregon 97205, United States
  • Dr. Harry Penny
    Altoona, Pennsylvania 16602, United States
  • Dr. Lawrence Parish
    Philadelphia, Pennsylvania 19103, United States
  • Dr. Cynthia Strout
    Mt. Pleasant, South Carolina 29464, United States
  • Dr. Teresa Coats
    Austin, Texas 78705, United States
  • Dr. Scott J. Ashton
    Dallas, Texas 75243, United States
  • Dr. Amit Pandya
    Dallas, Texas 75390-8802, United States
  • Dr. Lawrence Harkless
    San Antonio, Texas 78207, United States
  • Dr. Robert Shouey
    Harrisonburg, Virginia 22801, United States
  • Novartis Investigative Site
    Various cities, Canada
  • Novartis Investigative Site
    Various cities, Iceland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006 and a primary completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2007
First posted
Mar 7, 2007
Start
Dec 2006
Primary completionActual
Jun 2008
Results first posted
Apr 20, 2011
Last update
May 3, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00443898
Responsible party
Sponsor
First posted
Mar 7, 2007
Start date
Dec 2006
Primary completion
Jun 2008
Results posted
Apr 20, 2011
Last update
May 3, 2012

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Terbinafine

Start the discussion